PTI

Proteostasis Therapeutics Inc
NASDAQ

Bargain Price: 18.6$


Current Price 1.11 $
Industry Biotechnology
Sector Healthcare
Country US
Website click to visit
FT Employees 44
IPO Date 2016-02-11

Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the tr...eatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.

3 / 7

Size

5M

Current Ratio

6.88

Liquidity

61M

Net Income

0/10

Dividends

0/20

Earnings Growth

n/a

PE * PB

0.01